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Introduction
The use of illicit drugs and the misuse of drugs generally, is a major problem for individuals, families and communities 
across Europe. Apart from the health and social implications of drug misuse, the illicit drugs market constitutes a major 
element of criminal activity across European society and, indeed, on a global level.
In December 2012, the Council adopted the EU Drugs Strategy for 2013-2020. The Strategy aims to contribute to 
a reduction in drug demand and drug supply within the EU. It also aims to reduce the health and social risks and harms 
caused by drugs through a strategic approach that supports and complements national policies, that provides a frame­
work for coordinated and joint actions and that forms the basis and political framework for EU external cooperation in 
this field. This will be achieved through an integrated, balanced and evidence-based approach.
The objectives of the Strategy are:
— to contribute to a measurable reduction of the demand for drugs, of drug dependence and of drug-related health 
and social risks and harms,
— to contribute to a disruption of the illicit drugs market and a measurable reduction of the availability of illicit drugs,
— to encourage coordination through active discourse and analysis of developments and challenges in the field of 
drugs at EU and international level,
— to further strengthen dialogue and cooperation between the EU and third countries, international organisations and 
fora on drug issues,
— to contribute to a better dissemination of monitoring, research and evaluation results and a better understanding of 
all aspects of the drugs phenomenon and of the impact of interventions in order to provide a sound and compre­
hensive evidence base for policies and actions.
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This EU Drugs Action Plan, like the EU Drugs Strategy, is based on the fundamental principles of EU law and it upholds 
the founding values of the Union — respect for human dignity, liberty, democracy, equality, solidarity, the rule of law 
and human rights. It is also based on the UN Conventions that provide the international legal framework to address, 
inter alia, the use of illicit drugs, as well as on the Universal Declaration on Human Rights.
The Plan sets out the Actions that will be implemented to achieve the objectives of the Strategy. Actions are set out 
under the two policy areas of the Strategy:
— drug demand reduction, and
— drug supply reduction,
and the three cross-cutting themes of the Strategy:
— coordination,
— international cooperation, and
— information, research, monitoring and evaluation.
Actions are aligned to objectives of the EU Drugs Strategy 2013-2020. In drawing up the actions, account was taken of 
the need to be evidence-based, scientifically sound, realistic, time-bound, available and measurable with a clear EU rele­
vance and added value. This Action Plan indicates timetables, responsible parties, indicators and data collection/
assessment mechanisms.
Based on existing reporting mechanisms, a number of over-arching indicators are set out in Annex I. These facilitate the 
measurement of the overall effectiveness of this EU Drugs Action Plan and do not involve an additional reporting bur­
den. A number of these are referenced, as appropriate, across the Plan. Furthermore, throughout the Plan, indicators are 
set out that draw on programme, evaluative and other data sources. Utilisation of these indicators is dependent on data 
collection processes in each Member State or at EU institution level.
In line with the Strategy stipulation that its detailed implementation should be set out in two consecutive Action Plans, 
the first Action Plan implementing the current drugs strategy was adopted in 2013 and expired in 2016. In 2016, an 
external mid-term assessment of the EU Drugs Strategy and the implementation of the EU Drugs Action Plan 
2013-2016 was completed. The evaluation concluded that most of the actions foreseen in this Action Plan were con­
cluded or in progress. The results of the evaluation also demonstrated the need for the second Action Plan to implement 
the EU Drugs Strategy 2013-2020, which should be the updated version of the EU Action Plan on Drugs 2013-2016. 
The EU Drugs Action Plan 2017-2020 as provided below takes into account the results of this evaluation and the major 
changes in drug situation and policies since the adoption of the last Action Plan.
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1. Drug demand reduction
Contribute to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms as well as contribut­
ing to a delay in the onset of drug use
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
1. Prevent drug use and, sec­
ondly, delay the onset of drug use
1. Improve the availability and effective­
ness of evidence-based (1) prevention mea­
sures that take account of risk and protec­
tive factors as outlined below
a. population factors such as age; gender; 
education, cultural and social factors;
b. situational factors such as homeless­
ness; migration and asylum seeking, 
drug use in nightlife and recreational 
settings; the workplace; and driving 
under the influence of drugs; and
c. individual factors such as mental 
health; behaviour and psychosocial 
development; and other factors known 
to affect individual vulnerability to 
drug use such as genetic influences and 
family circumstances
Ongoing MS — Over-arching indicators 1, 11, 12
— Availability and level of provision at 
MS level of evidence-based universal 
and environmental prevention 
measures
— Availability and level of provision at 
MS level of evidence-based targeted 
prevention measures, including family 
and community based measures
— Availability and level of provision at 
MS level of evidence-based indicated 
prevention measures
EMCDDA Reporting/
Reitox network national 
reporting package
MS reporting on results 
of measures
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 2. In addition to the prevention of drug 
use, strengthen and better target preven­
tion and diversionary measures to delay 
the age of first use of illicit drugs and 
other psychoactive substances
Ongoing MS — Over-arching indicators 1, 5, 11, 12
— Availability and level of provision at 
MS level of evidence-based prevention 
and diversionary measures that target 
young people in family, community, 
and formal/non-formal education 
settings
EMCDDA Reporting
MS reporting on results 
of measures
 3. Exchange of best practices of all 
forms of prevention actions targeting chil­
dren and young people, parents and, edu­
cational environments whilst also taking 
into account gender-specific needs, includ­
ing educational activities, community 
based programmes, programmes using 
internet and social media.
Ongoing MS
EMCDDA
— Overview of exchanges of best prac­
tices between MS
— Positive evaluations of behavioural 
outcomes of best practice interven­
tions (where available)
EMCDDA Best Practice 
portal
COM Reporting
MS Reporting
Civil Society Forum on 
Drugs reporting
 4. Raise awareness of the risks and con­
sequences associated with the use of illicit 
drugs and other psychoactive substances 
and improve skills and competences for 
preventing drug use.
Ongoing MS
COM
EMCDDA
— Over-arching indicators 5, 12
— Level of awareness in general and 
youth populations of healthy lifestyles 
and of the risks and consequences of 
the use of illicit drugs and other psy­
choactive substances and level of the 
skills and competences of those 
involved in the prevention of drug use
EMCDDA Reporting
Eurobaro-meter surveys
ESPAD
HBSC/WHO Europe
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 5. Enable a more informed response to 
the challenge of the misuse of psychoac­
tive medicines.
2017-2020 MS
Council WP 
(HDG Pharma­
ceuticals and 
Medical Devices)
EMA
EMCDDA
— Number of initiatives that focus on the 
promotion of appropriate use of psy­
choactive medicines
— Collation of evidence and international 
examples on how to reduce the risks 
of diversion and misuse of psychoac­
tive medicines
— Number of courses for medical practi­
tioners and other health care profes­
sionals in the use of medication to 
control pain and treat suffering
MS Reporting
EMCDDA
Reporting EMA
2. Enhance the effectiveness of 
drug treatment and rehabilitation, 
including services for people with 
co-morbidity, to reduce the use of 
illicit drugs; problem drug use; the 
incidence of drug dependency and 
drug-related health and social risks 
and harms and to support the 
recovery and social re/integration of 
problematic and dependent drug 
users.
6. Develop and expand the diversity, 
availability, coverage and accessibility of 
evidence-based comprehensive and inte­
grated treatment services. Ensure that 
these services address polydrug use (com­
bined use of illicit and licit substances 
including psychoactive medicines, alcohol 
and tobacco) and the emerging needs of 
the ageing drug-using population and gen­
der-specific issues.
a. Implement and improve training for 
health care and social care profession­
als in addictive behaviours.
Ongoing MS — Over-arching indicators 1, 6, 11
— Extent and diversity of evidence-based 
comprehensive and integrated treat­
ment services at MS level including 
those which address polydrug use and 
the needs of the ageing drug-using 
population
— MS data on treatment retention and 
outcomes
EMCDDA Reporting/
Reitox network national 
reporting package
EMCDDA Best Practice 
Portal
EU Drugs Strategy and 
Action Plan final 
evaluation
MS Reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
b. Develop and implement early detection 
and intervention, brief intervention and 
treatment programmes for children and 
young people using drugs.
 7. Expand the provision of rehabilita­
tion/reintegration and recovery services 
with an emphasis on services that:
a. focus on providing a continuum of 
care through case management and 
interagency collaboration for 
individuals;
b. focus on supporting the social 
re/integration (including the employa­
bility and housing) of problem and 
dependent drug users including prison­
ers and ageing drug users, where 
relevant;
c. Strengthen the diagnostic process and 
the treatment of psychiatric and physi­
cal co- morbidity involving drug use, 
for e.g. with rapid testing for hepatitis 
B and C and HIV as well as other sexu­
ally transmitted infections and 
tuberculosis;
d. take account of gender-specific needs; 
and
e. reach out to vulnerable communities/
populations.
Ongoing MS — Over-arching indicator 11
MS data on:
— Extent of increase in rehabilitation/
reintegration and recovery services 
adopting case management and inter-
agency approaches
— Extent of increase in the number of 
gender specific rehabilitation/
reintegration and recovery 
programmes
— Extent of increase in the number of 
community care and prison pro­
grammes, specifically targeted at drug 
users with co-morbidity, involving 
partnerships between both mental 
health and drug rehabilitation/
reintegration and recovery services
— Level and duration of abstentions from 
consumption of illicit and/or licit 
drugs by people leaving drug 
treatment
— Availability of treatment options to 
meet needs of people who experience 
relapses to drug use and of ageing 
drug users
EMCDDA Reporting
MS Reporting on results 
of services
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 8. a. Scale up where applicable, avail­
ability, coverage and access to risk 
and harm reduction services e.g. 
needle and syringe exchange pro­
grammes, opioid substitution 
treatment, opioid overdose man­
agement programmes, to lessen 
the negative consequences of drug 
use and to prevent and to sub­
stantially reduce the number of 
direct and indirect drug-related 
deaths and infectious blood-borne 
diseases associated with drug use 
but not limited to HIV and viral 
hepatitis, as well as sexually trans­
mittable diseases and tuberculosis 
in accordance with the WHO rec­
ommendation on the comprehen­
sive package of health services for 
people who inject drugs
b. Better prevent drug related deaths 
according to national circum­
stances as for example in the case 
of opiates, by providing access to 
authorised pharmaceutical dosage 
forms of medicinal products con­
taining naloxone specifically certi­
fied to treat opioid overdose 
symptoms by trained laypersons 
in the absence of medical 
professionals
Ongoing MS
EMCDDA
COM
— Over-arching indicators 2, 3, 4, 11
— Extent of increased availability of and 
access to evidence-based risk and 
harm reduction measures in MS where 
applicable
— Overview of exchanges of best prac­
tices on risk and harm reduction 
measures
— Number of MS reaching the WHO rec­
ommendation on the comprehensive 
package of health services for people 
who inject drugs:
— Needle/Syringe programmes
— Opioid substitution treatment
— HIV testing and counselling
— HIV treatment and care
— Condom programmes
— Behavioural interventions
— Prevention and management of 
hepatitis, tuberculosis and mental 
health
— Sexual reproductive health 
interventions
— Naloxone training for laypersons as 
an irreplaceable prerequisite for 
safe take-home programmes
EMCDDA Reporting/
Reitox network national 
reporting package
MS Reporting
Civil Society Forum on 
Drugs
Civil Society Forum on 
HIV/AIDS, Viral Hepati­
tis and Tuberculosis
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
c. Identify and overcome barriers in 
detection and access to treatment 
for HIV and hepatitis C among 
people who inject drugs, includ­
ing prisoners and other vulnera­
ble groups
d. Exchange of information and 
where applicable best practice on 
risk and harm reduction measures 
such as, needle and syringe 
exchange programmes, opioid 
substitution treatment, drug con­
sumption rooms, naloxone pro­
grammes, peer-based interven­
tions, outreach treatment pro­
grammes, hepatitis C treatment, 
pill testing, self-testing for HIV/
AIDS, in accordance with national 
legislation
— Coverage of opioid substitution treat­
ment programmes among people with 
opioid dependence
— The extent of availability, where appli­
cable, of harm reduction services such 
as naloxone programmes, nightlife 
harm reduction measures and pro­
grammes targeting vulnerable 
communities/populations
— Number of programmes facilitating the 
access of people who inject drugs into 
treatment for the hepatitis C virus 
(HCV) and people covered
— Degree of implementation of ECDC/
EMCDDA guidance on prevention and 
control of infectious diseases among 
people injecting drugs
 9. Scale up the development, availabil­
ity and coverage of health care measures 
for drug users in prison and after release 
with the aim of achieving a quality of care 
equivalent to that provided in the 
community
Ongoing MS — Over-arching indicator 10
— Availability of services for drug users 
in prisons (such as opioid substitution 
treatment and if applicable, naloxone 
programmes and needle and syringe 
exchange programmes in accordance 
with national legislation and preven­
tion and management of HIV, Hepati­
tis B, Hepatitis C and TB) and the 
extent to which prison health care 
policies and practices incorporate care 
models comprising best practices in 
needs assessment and continuity of 
care for prisoners during 
imprisonment
EMCDDA Reporting/
Reitox network national 
reporting package
MS Reporting on 
services
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
— Extent to which prison based services 
and community based services provide 
continuity of care for prisoners upon 
release with particular emphasis on 
avoiding drug overdoses
3. Embed coordinated, best prac­
tice and quality approaches in drug 
demand reduction
10. Implement the EU minimum qual­
ity standards adopted by the Council in 
2015 (2) that help bridge the gap between 
science and practice, for:
a. environmental, universal, selective and 
indicated prevention measures;
b. early detection and intervention 
measures;
c. risk and harm reduction measures; and
d. treatment, rehabilitation, social integra­
tion and recovery measures
and monitor their implementation.
2017-2020 Council
Council WP 
(HDG)
MS
COM
EMCDDA
— Evidence review of drug demand 
reduction measures and programmes 
implemented in accordance with the 
standards;
— Number of specialist training pro­
grammes available for practitioners in 
drug demand reduction and/or esti­
mated number of practitioners reached 
by specialist training programmes;
— Involvement of civil society in the 
implementation of the standards, 
including in planning and introduction
— Number of projects and programmes 
supported at EU level that promote 
the exchange of best practices in the 
implementation of these standards
— Engagement in inter-ministerial coop­
eration to support implementation of 
these standards.
EMCDDA Best Practice 
Portal
MS Reporting
EU Drugs Strategy and 
Action Plan final 
evaluation
(1) Evidence-based should be read in this context as ‘based on available scientific evidence and experience’.
(2) Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding minimum quality standards in drug demand reduction in the European Union 11985/15.
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2. Drug supply reduction
Contribute to a measurable reduction of the availability and supply of illicit drugs in the EU
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
4. Enhance effective law enforce­
ment coordination and cooperation 
within the EU to counter illicit drug 
activity, in coherence, as appropri­
ate, with relevant actions deter­
mined through the EU policy cycle
11. Utilise to best effect available intelli­
gence and information sharing law 
enforcement instruments, channels and 
communication tools used to collate and 
analyse drug-related information
Ongoing MS
Europol
Eurojust
Council WP 
(COSI)
— Over-arching indicator 7, 15
— Extent of high impact intelligence led 
and targeted activities, of joint opera­
tions, joint investigation teams and 
cross border cooperation initiatives 
focusing on criminal organisations 
engaged in illicit drug activity
— Increased use of drug-related informa­
tion-sharing, analysis and expert sys­
tems of Europol or other law enforce­
ment authorities
— Results achieved from EMPACT 
projects and bilateral and multilateral 
initiatives
— Number of drug-related cases referred 
to Eurojust and Europol, including 
qualitative, contextual information 
about the cases
Europol Reporting
Eurojust Reporting
EMCDDA Reporting
EMPACT Driver Reports
 12. Identify and prioritise the most 
pressing threats associated with drug-
related organised crime
2017 Council
Council WP 
(COSI)
Europol
MS
COM
— EU Policy Cycle for organised and seri­
ous international crime for the period 
2018-2021 in place
EU SOCTA
Multi-annual Strategic 
Plans (MASPs)
Operational Plans
EMPACT Driver Reports
Europol Reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 13. Strengthen CEPOL's training for law 
enforcement officers in relation to illicit 
drug production, trafficking and financial 
crime, particularly training methods and 
techniques
a. to address the use of new communica­
tion technologies in illicit drug produc­
tion and trafficking;
b. to enhance asset confiscation;
c. to counter money laundering;
d. to detect and dismantle illicit clandes­
tine laboratories and cannabis cultiva­
tion sites.
2017-2020 MS
CEPOL
Europol
Council WP 
(COSI)
COM
— Training needs assessment carried out 
regularly
— Availability and uptake of relevant 
training courses
— Number of law enforcement officers 
trained and effectively deployed as 
a result
CEPOL Annual Report
CEPOL Curricula
EMPACT Driver Reports
 14. Improve counter-narcotic activities 
through strengthening and monitoring the 
effectiveness of regional information-shar­
ing platforms and regional security-shar­
ing platforms with the aim of disrupting 
and suppressing emerging threats from 
changing drug trafficking routes
Ongoing COM
MS
Europol
Council WP 
(COSI)
Regional 
Information-
Sharing 
Platforms
Regional 
Security-Sharing 
Platforms
— Over-arching indicator 7
— Number of intelligence-led activities 
leading to the disruption and suppres­
sion of drug trafficking routes
— Level of information sharing through 
effective activity of the liaison officer 
network
Security/Information -
sharing Platforms and 
Evaluation Reports
EMCDDA Reporting
EU SOCTA
EMPACT Driver Reports
Europol Reporting
MAOC(N) (1)
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 15. Strengthen actions to prevent the 
diversion of drug precursors and pre-pre­
cursors for use in the illicit manufacture 
of drugs
Ongoing MS
Europol
COM
Council WP 
(CUG
COSI)
— Number of cases and quantity of 
stopped or seized shipments of precur­
sors intended for illicit use
— Results achieved from EMPACT 
projects
— Use of Pre-Export Notification (PEN) 
Online System and increased use of 
the Precursors Incident Communica­
tion System (PICS)
— Number of joint follow-up meetings 
and other activities linked to the pre­
vention of the diversion of precursors 
and pre-precursors
Reports from EU and 
MS Law Enforcement 
Agencies
EMPACT
Driver Reports
Europol Reporting
 16. Counter cross-border drug traffick­
ing, including through container and par­
cel shipments, and improve border secu­
rity notably at EU seaports, airports and 
land border crossing points through inten­
sified efforts, including information and 
intelligence sharing, by relevant law 
enforcement authorities
Ongoing MS
Europol
Council WP
(CCWP
COSI)
— Number of multi-disciplinary/multi-
agency joint operations and cross bor­
der cooperation initiatives
— Intensified information exchange for 
example such as Memoranda of 
Understanding (MOU) agreed between 
law enforcement authorities and rele­
vant bodies such as airlines, air express 
couriers, shipping companies, harbour 
authorities and chemical companies
— Results achieved from EMPACT 
projects
— Improved intelligence and information 
sharing on cross-border drug traffick­
ing utilising, inter alia, available border 
surveillance systems
— Implementation of the EU Passenger 
Name Record (PNR) directive
EMPACT Driver Reports
Europol Reporting
Reports from the CCWP
MS Reporting
MAOC(N)
Frontex
C 215/32
EN
Official Journal of the European Union
5.7.2017
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 17. Implement the key indicators on 
drug supply reduction adopted by the 
Council in 2013 (2)
2017-2020 COM
MS
Council
Council WP 
(HDG)
EMCDDA
Europol
Extent of the implementation of the fol­
lowing indicators:
— number and quantity of drug seizures
— purity and content of drugs
— drug prices
— drug production facilities dismantled
— drug law offences
— drug availability in population surveys
— market size estimates
Overview of existing 
national drug supply 
data collection in MS
EMCDDA Reporting
Europol Reporting
5. Enhance effective judicial 
cooperation and legislation within 
the EU
18. Strengthen EU judicial cooperation 
in targeting cross-border drug trafficking, 
money laundering, and in the confiscation 
of the proceeds of drug-related organised 
crime
2017-2020 Council
COM
MS
Eurojust
— Timely implementation of agreed EU 
measures and legislation on (a) confis­
cation and recovery of criminal 
assets (3); (b) money laundering (4); 
(c) approximation of drug trafficking 
offences and sanctions across the 
EU (5)
— Increased number of financial investi­
gations and confiscations in relation to 
the proceeds of drug-related organised 
crime through EU law enforcement 
authorities and judicial cooperation
— Timely and effective responses to 
mutual legal assistance requests and 
European Arrest Warrants in relation 
to illicit drug trafficking
Eurojust Reporting
MS Reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 19. Adopt and implement new EU leg­
islative measures to address the emer­
gence, use and rapid spread of new psy­
choactive substances
2017-2020 COM
Council
Council WP 
(HDG)
MS
EMCDDA
Europol
EUROJUST
— EU legislation in place
— Implementation of EU legislation in 
MS
— Updating of EU guidelines for the 
information exchange and risk assess­
ment procedures
— Monitor the effects of new legislative 
measures with a special focus on the 
replacement-effect in the illegal drug 
market
MS Reporting
EMCDDA Reporting
COM
(EU measures)
 20. Implement EU legislation on drug 
precursors to prevent their diversion with­
out disrupting lawful trade
Ongoing Council
COM
MS
— Information on cases and quantity of 
stopped or seized shipments of precur­
sors intended for illicit use
— Results achieved from EMPACT 
projects
— Use of Pre-Export Notification (PEN) 
Online System and increased use of 
the Precursors Incident Communica­
tion System (PICS)
— Number of joint follow up meetings 
and other activities linked to the pre­
vention of the diversion of precursors 
and pre-precursors.
Annual INCB Precursor 
report
European Commission 
and EMCDDA reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 21. Address the use of certain pharma­
cologically active substances (as defined in 
Directive 2011/62/EU) as cutting agents 
for illicit drugs
Ongoing MS
COM
EMA
Europol
— Information on seizures of active sub­
stances used as cutting agents for illicit 
drugs
— Timely implementation of new EU leg­
islative requirements aimed at securing 
the supply chain for active substances 
under Directive 2011/62/EU, the Falsi­
fied Medicines Directive
Reports from the CCWP 
and CUG
MS Reporting
 22. Members States to provide and 
apply, where appropriate and in accor­
dance with their legal frameworks, alterna­
tives to coercive sanctions for drug using 
offenders, such as:
a. Education
b. (Suspension of sentence with) 
treatment
c. Suspension of investigation or 
prosecution
d. Rehabilitation and recovery
e. Aftercare and social reintegration
2017-2020 MS
Council WP 
(HDG
DROIPEN)
— Increased availability and implementa­
tion of alternatives to coercive sanc­
tions for drug-using offenders in the 
areas of education, treatment, rehabili­
tation, aftercare and social integration.
— Increased monitoring, implementation 
and evaluation of alternatives to coer­
cive sanctions
— Type and number of alternatives to 
coercive sanctions provided for and 
implemented by MS
— Information on the effectiveness of the 
use of alternatives to coercive 
sanctions
EMCDDA Reporting/
Reitox network national 
reporting package
MS Reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
6. Respond effectively to current 
and emerging trends in illicit drug 
activity
23. Identify strategic responses to 
address the role of new information com­
munication technologies (ICT) and the 
hosting of associated websites, in the pro­
duction, marketing, purchasing and distri­
bution of illicit drugs and new psychoac­
tive substances at national and EU level.
2017-2020 Council
COM
Council WP 
(HDG
COSI
CCWP)
MS
Europol
CEPOL
EMCDDA
EUROJUST
— Results achieved from law enforcement 
actions targeting drug-related crime 
via the internet
— Increased number of joint operations 
and cross border cooperation 
initiatives
— Number and impact of funded 
research projects and tools developed 
to support law enforcement
— Number of agreements/discussions 
with relevant industry partners
— Setting up of a glossary of terms
— Setting up of an inventory of monitor­
ing tools
— Numbers of training sessions for rele­
vant stakeholders
— Number of meetings with international 
partners in which the action was 
discussed
Interim Review of the 
EU Policy Cycle
EMPACT
Driver Reports
Europol Reporting
CEPOL Statistics/Annual 
Report
EMCDDA Reporting
MS Reporting
Reports from EU 
Agencies
COM
(1) MAOC (N), based in Lisbon, is an initiative by seven EU Member countries:  France, Ireland, Italy, Spain, Netherlands, Portugal and the UK, and is co-funded by the Internal Security Fund of the European 
Union. The Centre provides a forum for multi-lateral cooperation to suppress illicit drug trafficking by sea and air.
(2) Council conclusions on improving the monitoring of drug supply in the European Union 15 November 2013.
(3) Directive 2014/42/EU of the European Parliament and of the Council on the freezing and confiscation of instrumentalities and proceeds of crime in the European Union; Council Decision 2007/845/JHA con­
cerning  cooperation  between  Asset  Recovery  Offices  of  the  Member  States  in  the  field  of  tracing  and  identification  of  proceeds  of,  or  other  property  related  to,  crime;  Council  Framework 
Decision 2006/783/JHA on the application of the principle of mutual recognition to confiscation orders. Council Framework Decision 2003/577/JHA on the execution in the European Union of orders freez­
ing property or evidence, Commission proposal for a Regulation of the European Parliament and of the Council on the mutual recognition of freezing and confiscation orders COM(2016) 819; Council Frame­
work Decision 2005/212/JHA on confiscation of crime-related proceeds, instrumentalities and property; Council Framework Decision 2003/577/JHA on the execution in the European Union of orders freez­
ing property or evidence.
(4) Directive (EU) 2015/849 of the European Parliament and of the Council on the prevention of the use of the financial system for the purposes of money laundering or terrorist financing, amending Regulation 
(EU) No 648/2012 of the European Parliament and of the Council, and repealing Directive 2005/60/EC of the European Parliament and of the Council and Commission Directive 2006/70/EC; Council Frame­
work Decision 2001/500/JHA on money laundering, the identification, tracing, seizing and confiscation of instrumentalities and the proceeds of crime. Commission proposal for a Directive of the European 
Parliament and of the Council on countering money laundering by criminal law COM(2016) 826. Regulation (EU) 2015/847 of the European Parliament and of the Council on information accompanying 
transfers of funds and repealing Regulation (EC) No 1781/2006; Regulation (EC) No 1889/2005 of the European Parliament and of the Council on controls of cash entering or leaving the Community. Com­
mission proposal for a Regulation of the European Parliament and of the Council on controls on cash entering or leaving the Union and repealing Regulation (EC) No 1889/2005.
(5) Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking, as regards 
the definition of drug.
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3. Coordination
Member States and EU to effectively coordinate drugs policy
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
7. Ensure effective EU coordina­
tion in the drugs field
24. Enhance information-sharing 
between the HDG and other relevant 
Council Working Parties and in particular 
COSI to enhance coordination as regards 
the drug supply reduction pillar
Enhance information sharing between the 
HDG and other relevant geographical and 
thematic Council Working Parties includ­
ing such as COSI, COAFR, COASI, COEST, 
COLAC, COTRA, COWEB, CONUN, 
COHOM, CCWP, COSCE, CUG and 
DROIPEN
Ongoing PRES
Council
EEAS
Council WP 
(HDG)
— Extent to which the EU Drugs Strat­
egy/and Action Plan are taken into 
account in the Programmes of other 
Council Working Parties such as COSI, 
COAFR, COASI, COEST, COLAC, 
COTRA, COWEB, CONUN, COHOM, 
CCWP, COSCE, CUG and DROIPEN.
— Regular information point on the 
HDG agenda on (1) activities linked to 
drug-related priorities of the EU Policy 
Cycle (based on EMPACT reporting, 
once per Presidency); and (2) relevant 
activities of other Council Working 
Parties, in the presence of other rele­
vant Working Party Chairs, where 
appropriate
Council Working Party 
(HDG) reporting
Presidency Reporting
 25. Each Presidency may convene meet­
ings of the National Drugs Coordinators, 
and of other groupings as appropriate, to 
consider emerging trends, effective inter­
ventions and other policy developments of 
added value to the EU Drugs Strategy and 
to MS
Biannually PRES
MS
— Extent to which National Drug Coordi­
nators' meeting agenda reflects devel­
opments, trends and new insights in 
policy responses and provides for 
improved communication and infor­
mation exchange
Presidency Reporting
 26. The HDG will facilitate (a) monitor­
ing of the implementation of the Action 
Plan through thematic debates; and (b) an 
annual dialogue on the state of the drugs 
phenomenon in Europe
(a) Ongoing
(b) Annually
PRES
Council WP 
(HDG)
MS
COM
EMCDDA
Europol
— Extent of implementation of the 
Action Plan
— Number of actions from the Action 
Plan addressed in thematic debates in 
the HDG
— Timeliness of dialogue at the HDG on 
latest drug-related trends and data
Presidency Reporting
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 27. Ensure consistency and continuity 
of MS and EU actions across Presidencies 
to strengthen the integrated, balanced and 
evidence-based approach to drugs in the 
EU
Ongoing PRES
PRES Trio
MS
COM
Council WP 
(HDG)
EMCDDA
Europol
— Extent of consistency and continuity 
of actions across Presidencies
— Advancement in implementation of 
EU Drugs Strategy priorities across 
Presidencies
Presidency Reporting
 28. Ensure coordination of EU drugs 
policies and responses, to support interna­
tional cooperation between the EU, third 
countries and international organisations
Ongoing EEAS
COM
Council WP 
(HDG)
MS
— Level of consistency and coherence in 
the objectives, expected results and 
measures foreseen in EU actions on 
drugs
— Inclusion of drug-related priorities in 
strategies of relevant EU bodies
— Intensified cooperation between the 
HDG and the geographical/regional 
and thematic Council Working Parties, 
including COSI, COAFR, COASI, 
COEST, COLAT, COTRA, COWEB, 
CONUN and COHOM, CCWP, COSCE, 
CUG and DROIPEN
— Number of reports by Dublin Group
Periodical reporting by 
EEAS and COM to the 
Council Working Party 
(HDG)
Dublin Group
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
 29. a. Achieve a coordinated and 
appropriate level of resources at 
EU level and Member State level 
to fulfil the priorities of the EU 
Drugs Strategy
b. Strengthen the cooperation to 
tackle the rising trend of stimu­
lant addiction, in particular 
methamphetamine, between rel­
evant government bodies and 
the NGO sector, focusing on cre­
ating and sharing best practices 
in preventing the spread from 
local epidemics, including 
demand and supply reduction 
efforts, and sharing information 
on the prevention of misuse of 
medicinal products for metham­
phetamine production.
Annually
2017-2020
MS
COM
EEAS
Council
Council WP 
(HDG)
— Over-arching indicator 14
— Amount of funding at EU level, and 
where appropriate, MS level
— Extent of coordination on drugs-
related financial programmes across 
Council Working Parties and COM
— Level of networking between profes­
sionals from both statutory and non-
statutory sector
— Availability of accessible interventions
— Number of developed interventions
EMCDDA Reporting/
Reitox network national 
reporting package
COM Reporting
EMCDDA Best Practice 
portal
8. Ensure effective coordination 
of drug-related policy at national 
level
30. Coordinate actions on drugs policy 
between Government Departments/
Ministries and relevant agencies at MS 
level and ensure appropriate multi-disci­
plinary representation on, or input to, 
HDG delegations
Ongoing MS — Over-arching indicator 14
— Effectiveness of a horizontal drug pol­
icy coordination mechanism at MS 
level
— Number of cross-cutting actions in 
drug demand and supply reduction at 
Member State level
EMCDDA Reporting/
Reitox network national 
reporting package
MS Reporting
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9. Ensure the participation of 
civil society in drugs policy
31. Promote and strengthen dialogue 
with, and involvement of, civil society and 
the scientific community in the formula­
tion, implementation, monitoring and 
evaluation of drug policies at MS and EU 
levels
Ongoing MS
COM
Council WP 
(HDG)
PRES
— Timely dialogues between EU Civil 
Society Forum on Drugs and the HDG 
during each Presidency period
— Engagement of EU Civil Society Forum 
in reviewing implementation of the EU 
Drug Action Plan
— Level of involvement of civil society 
and the scientific community in MS 
and EU drug policy formulation, 
implementation, monitoring and 
evaluation
— Timely dialogue between the scientific 
community (natural and social sci­
ences, including neuroscience and 
behavioural research) and the HDG
Feedback from EU Civil 
Society Forum on Drugs 
and from Civil Society 
Representatives at MS 
and EU level
MS Reporting
Feedback from Scientific 
Community through the 
EMCDDA Scientific 
Committee
4. International cooperation
Strengthen dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive and balanced manner
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
10. Integrate the EU Drugs Strat­
egy within the EU's overall foreign 
policy framework as part of 
a comprehensive approach that 
makes full use of the variety of 
policies and diplomatic, political 
and financial instruments at the 
EU's disposal in a coherent and 
coordinated manner
32. Ensure policy coherence between 
the internal and external aspects of the EU 
drug policies and fully integrate drug 
issues within the political dialogues and 
framework agreements between the EU 
and its partners and in the EU advocacy 
on global issues or challenges
Ongoing COM
EEAS
PRES
Council WP 
(HDG)
MS
— Over-arching indicator 13
— Drug policy priorities increasingly 
reflected in EU's external policies and 
actions
— Inclusion of drug-related priorities in 
EU strategies with third countries and 
regions
— Number of agreements, strategy 
papers, action plans in place
EEAS Reporting
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 33. Ensure that the policy priorities and 
the balance between demand and supply 
reduction are well reflected in policy 
options and in the programming, imple­
mentation and monitoring of external 
assistance, particularly in source and tran­
sit countries, through projects involving:
a. development of integrated, balanced 
and evidence-based drug policies;
b. supply reduction;
the prevention of the diversion of drug 
precursors and pre-precursors;
c. drug demand reduction; and
d. alternative development measures
Ongoing COM
MS
EEAS
— Extent to which EU's Drug policy pri­
orities, especially the balance between 
demand and supply reduction, are 
reflected in funded priorities and 
projects
— Level of implementation of coordi­
nated actions in action plans between 
the EU and third countries and regions
— Number of third country national 
strategies and action plans that incor­
porate integrated drug policies
COM, EEAS and MS 
programming pro­
gramme monitoring and 
evaluation reports
 34. Improve capacity and strengthen 
the role of EU Delegations to enable them 
to proactively engage on drug policy 
issues and effectively report back on the 
local situation on drugs
2017-2020 EEAS
COM
MS
— Relevant expertise, training and policy 
guidance provided to EU Delegations
— Regional networking among EU Dele­
gations on drug issues enhanced
— Coordination with MS enhanced
EEAS and COM 
Reporting
EU Delegations
Dublin Group Reports
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 35. Promote and implement the EU 
approach to alternative development (con­
sistent with the EU Drug Strategy 
2013-2020; the EU Approach to Alterna­
tive Development and the United Nations 
Guiding Principles on Alternative Devel­
opment 2013) in cooperation with third 
countries, taking into account human 
rights, human security, gender aspects and 
specific framework conditions, including:
a. incorporating alternative development 
into the broader agenda of Member 
States, encouraging third countries that 
wish to do so to integrate alternative 
development into their national 
strategies;
b. contributing to initiatives that aim to 
reduce poverty, conflict and vulnerabil­
ity by supporting sustainable, legal and 
gender sensitive livelihoods for people 
who were previously, or are currently, 
involved in illicit drug crop cultivation
Ongoing MS
COM
EEAS
— Number of third country national poli­
cies, strategies and action plans that 
incorporate:
— integrated approaches to the prob­
lem of illicit drug crop cultivation 
and
— effectively organised alternative 
development initiatives
— Number of evaluated projects that 
demonstrate positive outcomes relat­
ing to sustainable, legal and gender 
sensitive livelihoods
— Improvements in human development 
indicators
— Number of rural development projects 
and programmes, funded by the EU 
and MS in regions where illicit drug 
crop cultivation is taking place, or in 
regions at risk of illicit drug crop 
cultivation
— Reported local decrease in illicit drug 
crop cultivation in the long-term
UNODC and INCB 
reports on drug policies 
in non-EU countries
EU and MS Project and 
Programme Monitoring 
and Evaluation Reports
UNDP Human Develop­
ment Reports
Dublin Group reporting 
on non-EU countries
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c. providing an appropriate level of EU 
and MS funding and expertise to fur­
ther strengthen and support non-EU 
countries' efforts in addressing and pre­
venting illicit drug crop cultivation, 
through rural development measures 
and strengthening the rule of law in 
order to deal with the challenges of 
poverty reduction, public health, safety 
and security
 36. Support third countries, including 
civil society in those countries, to develop 
and implement risk and harm reduction 
initiatives particularly where there is 
a growing threat of transmission of drug-
related blood-borne viruses associated 
with drug use including but not limited to 
HIV and viral hepatitis, as well as sexually 
transmittable diseases and tuberculosis
Ongoing MS
COM
EEAS
— Number and quality of risk and harm 
reduction initiatives developed
— Prevalence of drug-related deaths in 
third countries and drug-related blood-
borne viruses including but not lim­
ited to HIV and viral hepatitis, as well 
as sexually transmittable diseases and 
tuberculosis
WHO Reports
Dublin Group reporting 
on non-EU countries
EEAS, COM and MS 
exchanges on the poli­
cies of non-EU countries
 37. Support third countries to tackle 
drug-related organised crime, including 
drug trafficking, by:
a. intelligence-sharing and the exchange 
of best practices;
b. strengthening counter-narcotics capac­
ity and developing expertise of source 
and transit countries;
Ongoing MS
EEAS
COM
Europol
— Number and effectiveness of projects 
and programmes by the EU and the 
MS in non-EU countries
— Sustained reduction in drug trafficking
COM and MS Reporting
Europol Reporting
EEAS Reporting
UNODC Annual World 
Drug Report
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c. working with international partners to 
tackle the enablers of drug trafficking 
such as corruption, weak institutions, 
poor governance and lack of financial 
regulatory controls;
d. strengthening cooperation in the field 
of asset identification and recovery, in 
particular through the creation of dedi­
cated national platforms; and
e. intensifying regional and intra-regional 
cooperation
f. incorporating rule-of-law and interna­
tional human rights standards and 
principles in drug-related law enforce­
ment measures
 38. a. Reinforce cooperation and/or 
conduct dialogue with partners, 
including:
— Acceding countries, candi­
date countries and potential 
candidates
— European Neighbourhood 
Policy countries
— United States of America
— Russian Federation
Ongoing PRES Trio
COM
EEAS
MS
— Over-arching indicator 13
— Strengthened cooperation in the field 
of drugs with relevant partners
— Dialogues organised
— Declarations agreed
— Programmes and Action Plans 
implemented
EEAS Reporting
Implementation Reports 
of the relevant action 
plans where available
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— Other countries or regions of 
priority notably:
— Afghanistan, Pakistan and 
Iran
— Central Asian Republics
— China
— Latin American and the 
Caribbean (CELAC)
— Africa, in particular West 
Africa
— Other countries depending 
on national and international 
developments
b. Explore possibilities for engage­
ment (such as bilateral dialogues, 
joint projects) with other non-
EU countries on serious drug-
related issues
 39. Improve the Dublin Group consul­
tative mechanism through intensified EU 
coordination and participation, better for­
mulation, implementation and dissemina­
tion of its recommendations
Ongoing Dublin Group
COM
EEAS
MS
— Level of activity across Dublin Group 
structures including number of Dublin 
Group recommendations effectively 
implemented
— Achieved modernisation of the Dublin 
Group's working methods
Dublin Group Reports
 40. Hold an annual dialogue on EU and 
MS drugs-related assistance to third coun­
tries accompanied by a written update
From 2017 COM
EEAS
MS
— Presentation by COM and EEAS to the 
Horizontal Drugs Group, at least once 
a year
COM and EEAS 
Reporting
MS Reporting
Project and Programme 
Monitoring and Evalua­
tion System and Reports
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 41. Ensure that the promotion and pro­
tection of human rights are fully inte­
grated in political dialogues and in the 
planning and implementation of relevant 
drugs-related programmes and projects 
including through the implementation of 
the rights-based approach (RBA) and of 
tailored human rights guidance and 
impact assessment tool
Ongoing COM
COHOM/EEAS
MS
— Human rights effectively mainstreamed 
into EU external drug-related policies 
and actions
— Human rights guidance and assess­
ment tool implemented
EU Annual Report on 
Human Rights
MS Reporting
11. Improve cohesiveness of EU 
approach and EU visibility in the 
United Nations (UN) and strengthen 
EU coordination with international 
bodies related to the drugs field
42. Contribute to shaping the agenda 
on international drugs policy, including 
through:
a. More affirmative action by EU and MS 
Delegations at the UN General Assem­
bly and the Commission on Narcotic 
Drugs (CND);
b. Coordinated action by EU and MS dele­
gations in all other UN fora addressing 
drug-related matters (e.g. World Health 
Assembly, Human Rights Council, High 
Level Political Forum on Sustainable 
Development)
Ongoing EEAS
PRES
MS
COM
Council
Council WP 
(HDG)
— Over-arching indicator 13
— Number of EU statements delivered at 
CND and other UN fora
— Number of EU common positions sup­
ported by other regions and interna­
tional bodies
— Number of EU common positions 
concerning CND decisions on schedul­
ing of substances
— Outcome of the CND decisions on 
scheduling of substances
EEAS Reporting
Convergence Indicator
2019 review Outcome
The Sustainable Devel­
opment Goals annual 
reports
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c. preparation, coordination and adoption 
of EU common positions and joint res­
olutions in the UN General Assembly 
and the CND, including, ahead of the 
CND, on scheduling of substances, and 
ensuring that the EU speaks with one 
strong voice in these and other interna­
tional fora;
d. promotion and monitoring the imple­
mentation of the recommendations of 
the 2016 UNGASS Outcome Docu­
ment as a pivotal reference document 
for discussions of relevance to interna­
tional drug policy in all pertinent fora
e. the ministerial segment to be held dur­
ing the sixty-second session of CND, in 
Vienna in 2019; and
f. ensure the meaningful involvement of 
civil society and the scientific commu­
nity in the review process
— Level of successful adoption of EU res­
olutions at UN including at the CND
— Effective promotion of EU policies in 
the UN, including at the CND
— Adoption of an EU Common Position 
Paper for the 2019 review process; EU 
contribution to the definition by the 
CND on the modalities for the 2019 
process
— Implementation of EU common posi­
tion on the post-UNGASS process
— Outcome of the 2019 review of the 
UN Political Declaration and Action 
Plan on International Cooperation 
towards an Integrated and Balanced 
Strategy to Counter the World Drug 
Problem
— Progress in implementation of drug-
related Sustainable Development Goals 
(SDGs)
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 43. Strengthen partnerships with the 
UNODC, WHO, UNAIDS and other rele­
vant UN agencies, international and 
regional bodies and organisations and ini­
tiatives (such as the Council of Europe and 
the Paris Pact Initiative)
Ongoing Council
EEAS
COM
PRES
Council WP 
(HDG)
EMCDDA
— Over-arching indicators 13, 15
— Number of information exchanges and 
activities between the EU and relevant 
international and regional bodies and 
organisations and initiatives
— Effectiveness of partnerships with rele­
vant bodies
MS, EEAS, COM 
Reporting
12. Support the process for 
acceding countries, candidate coun­
tries, and potential candidates to 
adapt to and align with the EU 
acquis in the drugs field, through 
targeted assistance and monitoring
44. Provide targeted technical assis­
tance, and other assistance and support as 
necessary, to acceding countries, candidate 
countries, and potential candidates to 
facilitate their adaptation to and alignment 
with the EU acquis in the drugs field
Ongoing COM
MS
EMCDDA
Europol
Eurojust
Frontex
EEAS
— Over-arching indicator 15
— Increased compliance by countries 
with EU acquis
— Number and quality of completed 
projects
— National Drug Strategies and national 
drug coordinating structures 
established
EMCDDA Reporting
Acceding countries, can­
didate countries and 
potential candidates 
reports
5. Information, research, monitoring and evaluation
Contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of measures in order to provide sound and comprehensive evidence for 
policies and actions
Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
13. Ensure adequate investment 
in research, data collection, moni­
toring, evaluation and information 
exchange on all aspects of the drug 
phenomenon
45. Promote appropriate financing of 
EU-level drug-related multi-disciplinary 
research and studies including through EU 
related financial programmes (2014-2020)
2017-2020 MS
COM
— Amount and type of EU funding pro­
vided across the different programmes 
and projects
COM
Reporting at annual 
research dialogue
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 46. Ensure that EU-supported projects:
a. take account of the priorities of the EU 
Drug Strategy and Action Plan on 
Drugs;
b. take account of gaps in policy 
formulation;
c. deliver clear added value and ensure 
coherence and synergy; and
d. avoid duplication with research under 
other programmes and bodies
e. take account of the importance of 
behavioural research and 
neuroscience (1)
f. include clear indicators for measuring 
their impact
2017-2020 COM
EMCDDA
— The inclusion of the priorities of the 
EU Strategy and Action Plan on Drugs 
in the funding and assessment criteria 
of EU-funded drug-related research
— Number, impact, complementarity and 
value of EU-funded drug-related 
research grants and contracts awarded
— Number of EU-funded drug- related 
articles and research reports published 
in peer-reviewed journals with high 
impact factors
— Annual debate at the HDG on drug-
related research projects funded by the 
EU including EMCDDA Scientific 
Committee recommendations on 
research priorities
Research project reports
EMCDDA Scientific 
Committee recommen­
dations on research 
priorities
Science Citation Index 
and similar bibliometric 
tools
Strategic research agenda 
developed by ERANID
 47. Promote evidence-based evaluations 
of policies and interventions at national, 
EU and international level
2017-2020 COM
MS
EMCDDA
— Over-arching indicator 14
— EMCDDA guide on evaluation used to 
support national process
— Delivery of dedicated studies into the 
effectiveness and impacts of EU and 
international drug policies
EMCDDA Reporting/
Reitox network national 
reporting package
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 48. Reinforce analysis (including map­
ping information sources) and information 
sharing on the relationship between drugs 
trafficking and:
a. financing of terrorist groups and activi­
ties, including any overlap between the 
established routes for drug production 
and trafficking areas and conflict 
zones; and financing sources of terror­
ist cells in the EU from illicit activities, 
including drug trafficking;
b. migrant smuggling (building synergies 
with the EU Action Plan against 
migrant smuggling (2015-2020) that 
foresees research and risk analysis 
between smuggling and other crimes 
such as drug trafficking) including:
— A focus on vulnerable migrants and 
their potential exploitation for drug 
trafficking purposes and/or as end-
users of drugs, in particular minors 
and women.
— Exploration of any overlap between 
drug trafficking and migrant smug­
gling criminal rings, modi operandi 
and routes.
2017-2020 MS
Commission
EU ATC
EMCDDA
Europol
Frontex
FRA
EIGE
Council WP
(COSI
COTER
TWP
HLWG)
— Extent to which understanding is 
increased of the potential connections 
between drug trafficking and:
— Terrorist financing
— Migrant smuggling
— Trafficking in Human Beings
— EU and national outputs (such as 
reports, studies and articles addressing 
these topics)
MS reporting
COM reporting
EU agencies reporting 
(EMCDDA Europol
Frontex and FRA in the 
framework of their regu­
lar reporting activities
EIGE in the framework 
of their regular reporting 
activities
FATF Risk Assessments
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c. trafficking in human beings building 
synergies with the EU legal and policy 
framework addressing trafficking in 
human beings including the EU Strat­
egy towards the Eradication of Traffick­
ing in Human Beings 2012–2016
14. Maintain networking and 
cooperation and develop capacity 
within and across the EU's knowl­
edge infrastructure for information, 
research, monitoring and evaluation 
of drugs, particularly illicit drugs
49. In collaboration with relevant par­
ties continue to provide comprehensive 
analyses of:
a. the EU drug situation;
b. the dynamics of drug use within gen­
eral populations and target groups
c. responses to drug use
and in due course to provide an update by 
the EMCDDA of the 2017 overview of 
cannabis legislation in the EU as well as 
continue to monitor and report on 
cannabis legislations at national level and 
in third countries
Ongoing EMCDDA
Europol
MS
COM
— Over-arching indicators 1-15
— Current deficits in the knowledge base 
established and an EU level framework 
developed to maximise analyses from 
current data holdings
— Number of overviews and topic analy­
ses on the drug situation
EMCDDA Reporting
MS Reporting
Civil Society Forum on 
Drugs
COM
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 50. Enhance evidence-based training for 
those involved in responding to the drug 
phenomenon
2017-2020 MS
EMCDDA
CEPOL
— Number of initiatives at MS and EU 
level to train professionals in aspects 
of drug demand reduction and drug 
supply reduction
— Number of initiatives at MS and EU 
level implemented to train profession­
als related to data collection and 
reporting of drug demand reduction 
and drug supply reduction
MS Reporting
CEPOL Annual Report
EMCDDA Reporting/
Reitox network national 
reporting package
 51. Enhance data collection, research, 
analysis and reporting on:
a. drug demand reduction;
b. drug supply reduction;
c. emerging trends, such as polydrug use 
and misuse of psychoactive medicines, 
that pose risks to health and safety;
d. blood-borne viruses associated with 
drug use including but not limited to 
HIV and viral hepatitis, as well as sexu­
ally transmittable diseases and 
tuberculosis;
e. psychiatric and physical co-morbidity;
Ongoing MS
COM
EMCDDA
Europol
ECDC
EMA
— Increased availability and implementa­
tion of evidence-based and scientifi­
cally sound indicators on drug supply 
reduction and drug demand reduction
— At MS level, extent of new research 
initiated on emerging trends such as 
polydrug use and the misuse of psy­
choactive medicines; blood-borne dis­
eases associated with drug use includ­
ing but not limited to HIV and viral 
hepatitis, as well as sexually transmit­
table diseases and tuberculosis; psychi­
atric and physical co-morbidity; and 
other problems and consequences 
related to both licit and illicit 
substances
EMCDDA Reporting
EMA Reporting
MS Reporting
Harmonised data reports 
from EU bodies includ­
ing EMCDDA
EU SOCTA
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f. drug problems among prisoners and 
the availability and coverage of drug 
demand reduction interventions and 
services in prison settings; and
g. other problems and consequences 
related to illicit substances as well as to 
polydrug use (combined use of illicit 
and licit substances including psy­
choactive medicines, alcohol and 
tobacco)
h. compliance of drug policies with inter­
national human rights standards and 
principles
— EU-wide study carried out on drug-
related community intimidation and 
its impact on individuals, families and 
communities most affected and effec­
tive responses to it
— Adoption of evidence-based and scien­
tifically sound indicators on drug 
problems among prisoners
 52. Improve the capacity to detect, 
assess and respond effectively to the emer­
gence and use of new psychoactive sub­
stances and monitor the extent to which 
such new substances impact on the num­
ber and profile of users
Ongoing COM
MS
EMCDDA
Europol
— Over-arching indicator 6
— Extent of new epidemiological, phar­
macological and toxicological research 
initiated on new psychoactive sub­
stances and supported by MS and EU 
Research programmes
— Extent of information, best practice 
and intelligence exchange
— Extent of sharing by toxicology labora­
tories and by Research Institutes of 
toxicological and health data analyses 
on new psychoactive substances
EMCDDA Reporting/
Reitox network national 
reporting package
EMCDDA-Europol 
Implementation Report
Reports by laboratories 
and research institutes
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 53. Strengthen efforts to share forensic 
science data, including support on the 
identification of new psychoactive sub­
stances, laboratory reference standards on 
new psychoactive substances, and the 
development of a common methodology 
for the identification of new substances by 
enhancing cooperation with the Commis­
sion's Joint Research Centre, and through 
existing networks, such as the Drugs 
Working Group of the European Network 
of Forensic Science Institutes in the frame­
work of the JHA Council Conclusions on 
the Vision for European Forensic Science 
2020 and the Customs Laboratories Euro­
pean Network
2017-2020 COM
MS
EMCDDA
— Over-arching indicator 15
— Extent of sharing of forensic science 
data on new psychoactive substances, 
supporting the identification of new 
psychoactive substances
— Ease of access to laboratory reference 
standards by forensic science laborato­
ries, customs laboratories and 
institutes
— Progress on development of 
a common methodology for the iden­
tification of new psychoactive 
substances
EMCDDA/Europol 
Reporting
COM Reporting
 54. Improve and increase the ability to 
identify, assess and respond at MS and EU 
levels to (a) behavioural changes in drug 
consumption; and (b) to drug-related epi­
demic outbreaks
Ongoing MS
EMCDDA
ECDC
— Number and effectiveness of new 
drug-related public health initiatives 
developed and implemented
— Number and effectiveness of existing 
measures and initiatives that are 
adjusted to take account of drug con­
sumption or epidemic outbreaks
— Number and impact of early warning 
reports, risk assessment and alerts
Early Warning System 
reports
EMCDDA Reporting/
Reitox network national 
reporting package
EMA Reporting
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Objective Action Timetable Responsible party Indicator(s) Data collection/assessment mechanisms
15. Enhance dissemination of 
monitoring, research and evaluation 
results at EU and national level
55. Member States continue to support 
EU monitoring and information exchange 
efforts, including cooperation with, and 
adequate support for, Reitox National 
Focal Points
a. Organisation of European events 
focused on the transfer and dissemina­
tion of knowledge from research to 
policy makers and professionals
Ongoing MS
EMCDDA
COM
— Open-access outputs from EU funded 
studies disseminated
— Extent to which Reitox National Focal 
Points funding and other resources 
match requirements
— Number and effectiveness of Reitox 
National Focal Points dissemination 
initiatives
— Number of EU events organised on the 
transfer and dissemination of knowl­
edge from research to policy makers 
and professionals
Web Dissemination 
including OpenAire, 
Cordis
EMCDDA website
EMCDDA Reporting/
Reitox network national 
reporting package
(1) Under Horizon 2020 (2014-2020), some EUR 27 million have already been allocated to projects addressing drug addiction and include behavioural research and neuroscience.
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ANNEX I
15 over-arching indicators for the EU Action Plan on Drugs 2017-2020 (1)
1. Percentage of population who use drugs currently (within last month), used drugs recently (within last year), and 
who have ever used (lifetime use) by drug and age group (EMCDDA General Population Survey)
2. Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem Drug Use)
3. Trends in drug induced deaths and mortality amongst drug users (according to national definitions) (EMCDDA 
Drug-related Deaths)
4. Prevalence and incidence, among injecting drug users, of infectious diseases attributable to drug use, including 
HIV and viral Hepatitis, sexually transmittable diseases and tuberculosis (EMCDDA Drug-related Infectious Diseases)
5. Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and Drugs (ESPAD), 
Health Behaviour in School-aged Children (HBSC) and General Population Drug Use Survey (EMCDDA Key Epidemio­
logical Indicator)
6. Trends in numbers of people entering drug treatment (EMCDDA Treatment Demand) and the estimated total 
number of people in drug treatment (EMCDDA Treatment Demand and Health and Social Responses)
7. Trends in number of and quantities of seized illicit drugs (EMCDDA Drug Seizures: cannabis incl. herbal cannabis, 
heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD and other substances)
8. Trends in retail price and purity of illicit drugs (EMCDDA Price and Purity: cannabis incl. herbal cannabis, heroin, 
cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD, other substances and composition of drug 
tablets)
9. Trends in the number of initial reports of drug law offences, by drug and type of offence (supply vs use/posses­
sion) (EMCDDA Drug Offences)
10. Prevalence of drug use amongst prisoners (EMCDDA Drug Use in Prisons)
11. Assessment of availability, coverage and quality of services and interventions in the areas of prevention, harm 
reduction, social integration and treatment. (EMCDDA Health and Social Responses)
12. Evidence-based interventions on prevention, treatment, social integration and recovery and their expected impact 
on drug use prevalence and problem drug use (EMCDDA Best Practice Portal)
13. Strong dialogue and cooperation, in the drugs related field, with other regions, third countries, international 
organisations and other parties (EEAS reporting)
14. Developments in national drug strategies, evaluations, legislation, coordination mechanisms and public expendi­
ture estimates in EU Member States (EMCDDA)
15. Early Warning System on new psychoactive substances (EMCDDA/Europol) and Risk Assessment on new psy­
choactive substances (EMCDDA)
(1) These indicators are based on existing reporting systems that pre-date the objectives of the current EU drug strategy and action plan, 
but provide the most comprehensive set of EU-level resources to support their monitoring and evaluation.
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ANNEX II
Glossary of acronyms
CCWP Council of the EU — Customs Cooperation Working Party
CELAC Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin American and Caribbean 
States)
CEPOL European Police College
CND Commission on Narcotic Drugs (UN)
COAFR Council of the EU — Africa Working Party
COASI Council of the EU — Asia-Oceania Working Party
COEST Council of the EU — Working Party on Eastern Europe and Central Asia
COHOM Council of the EU — Working Party on Human Rights
COLAC Council of the EU — Working Party on Latin America
COM European Commission
CONUN Council of the EU — United Nations Working Party
COSCE Council of the EU — Working Party on OSCE and the Council of Europe
COSI Council of the EU — Standing Committee on Operational Cooperation on Internal Security
COTRA Council of the EU — Working Party on Transatlantic Relations (Canada and the USA)
Council WP Council Working Party
COTER Council of the EU — Working Party on Terrorism (International Aspects)
COWEB Council of the EU — Working Party on the Western Balkans Region
CUG Council of the EU — Customs Union Group
DROIPEN Council of the EU — Working Party on Substantive Criminal Law
ECDC European Centre for Disease Control
EEAS European Union External Action Service
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform against Criminal Threats
ENFSI European Network of Forensic Science Institutes
ERA-net European Research Area — Network
ERANID European Research Area Network on Illicit Drugs
ESPAD European School Survey Project on Alcohol and Drugs
EU European Union
EUROJUST European Judicial Cooperation Unit
EUROPOL European Union Agency for Law Enforcement Cooperation
EU SOCTA EU Serious and Organised Crime Threat Assessment
Frontex European Agency for the Management of Operational Cooperation at the External Borders of the Member 
States of the European Union
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HBSC Health Behaviour in School Aged Children survey
HCV Hepatitis C virus
HDG Council of the EU — Horizontal Working Party on Drugs
HIV Human immunodeficiency virus
HLWG Council of the EU — High-Level Working Group on Asylum and Migration
INCB International Narcotics Control Board (UN)
JHA Justice and Home Affairs
LGBTI Lesbian, Gay, Bisexual, Transgender/Transsexual and Intersexed
LSD Lysergic acid diethylamide
MAOC (N) The Maritime Analysis and Operations Centre
MASPs Multiannual Strategic Plans (Europol)
MOU Memorandum of Understanding
MS Member State
NPS New psychoactive substances
PEN UNODC/INCB developed Pre-Export Notification Online System
PICS Precursors Incident Communication System
PRES Rotating Presidency of the Council of the European Union
PRES Trio Grouping of three consecutive rotating Presidencies of the Council of the European Union
Reitox Réseau Européen d’Information sur les Drogues et les Toxicomanies
SOCTA Serious and Organised Crime Threat Assessment
TWP Council of the EU — Working Party on Terrorism
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNGASS United Nations General Assembly Special Session
UNODC United Nations Office on Drugs and Crime
UNDP United Nations Development Programme
WHO World Health Organisation (UN)
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